Canna~Fangled Abstracts

Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy

By August 8, 2022No Comments

doi: 10.1007/s00520-022-07312-y.

Online ahead of print.


Purpose: To assess the safety, dosing, and preventive effects of cannabidiol (CBD) on chemotherapy-induced peripheral neuropathy (CIPN) in patients receiving oxaliplatin- or paclitaxel-based chemotherapy.

Methods: Patients with cancer scheduled to undergo treatment with carboplatin and paclitaxel (Carbo-Tax) or capecitabine and oxaliplatin (CAPOX) received 150 mg CBD oil twice daily (300 mg/daily) for 8 days beginning 1 day before initiation of chemotherapy. Ten CIPN-specific patient-reported outcome (PRO) measures were captured at baseline and each day after the first cycle of chemotherapy for 8 days. Multi-frequency vibrometry (MF-V) was captured at baseline and day 4 ± 1 after initiation of chemotherapy. Controls were obtained from a similar patient cohort that did not receive CBD. Adverse events were captured using the CTCAE ver. 4.03.

Results: From March to December 2021, 54 patients were recruited. CBD-treated patients were significantly older (p = 0.013/0.037, CAPOX/Carbo-Tax) compared to controls. Patients receiving CBD and CAPOX or Carbo-Tax showed significantly lower (better) change in Z-scores in high-frequency MF-V (125 and 250 Hz) compared to controls. This difference was most pronounced for patients receiving Carbo-Tax (- 1.76, CI-95 = [- 2.52; – 1.02] at 250 Hz). CAPOX patients treated with CBD had significantly lower peak baseline-adjusted difference in three PRO items on cold sensitivity to touch, discomfort swallowing cold liquids, and throat discomfort (- 2.08, – 2.06, and – 1.81, CI-95 = [- 3.89; – 0.12], NRS 0-10). No significant differences in PRO items were found for patients receiving Carbo-Tax. Possible side effects included stomach pain (grades 1-2) for patients receiving CAPOX.

Conclusion: CBD attenuated early symptoms of CIPN with no major safety concerns. Long-term follow-up is ongoing. Results should be confirmed in a larger, randomized study.

Trial registration number: NCT 04,167,319 (U.S National Library of Medicine; Date of registration: November 18, 2019.

Keywords: Cannabinoid, Chemotherapy-induced peripheral neuropathy, Oxaliplatin-induced peripheral neuropathy, Paclitaxel-induced peripheral neuropathy, Peripheral neuropathy

Similar articles


    1. Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155:2461–2470. – DOI – PubMed
    1. Miura Y, Ando M, Yamazaki K et al (2021) Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2). Support Care Cancer 29:3715–3723. – DOI – PubMed
    1. Pellacani C, Eleftheriou G (2020) Neurotoxicity of antineoplastic drugs: mechanisms, susceptibility, and neuroprotective strategies. Adv Med Sci 65:265–285. – DOI – PubMed
    1. Si Z, Zhang S, Yang X et al (2019) The association between the incidence risk of peripheral neuropathy and PD-1/PD-L1 inhibitors in the treatment for solid tumor patients: a systematic review and meta-analysis. Front Oncol 9:1–10. – DOI
    1. Laforgia M, Laface C, Calabrò C et al (2021) Peripheral neuropathy under oncologic therapies: a literature review on pathogenetic mechanisms. Int J Mol Sci 22:1980. – DOI – PubMed – PMC

LinkOut – more resources

Leave a Reply

en English